Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 139, Issue 1-2, Pages 150-154Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S0165-5728(03)00154-1
Keywords
leptin; cytokines; multiple sclerosis; interferon beta
Categories
Ask authors/readers for more resources
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after I year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy. (C) 2003 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available